Health ❯ Healthcare ❯ Medical Research

Oncology

Lung Cancer Breast Cancer Prostate Cancer Pancreatic Cancer Glioblastoma Colorectal Cancer Acute Myeloid Leukemia Multiple Myeloma Clinical Trials Immunotherapy

4 ARTICLES

3w ago

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

Topline phase 1/2 results suggest the MTAP‑deleted, RAS‑mutant combination could enable a precision, chemotherapy‑sparing first‑line approach if randomized trials confirm the finding.

4 ARTICLES

last mo.

Tumor Inflammation Drives Early Resistance to KRAS Drugs, Study Shows

5 ARTICLES

last mo.

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

3 ARTICLES

last mo.

Boehringer’s Zongertinib Wins China Conditional Approval as ASCO Data Show Patient Benefit and Broader Activity

5 ARTICLES

last mo.

GLP-1 Drugs Linked to Lower Death and Recurrence in Breast Cancer, Large Study Finds

11 ARTICLES

last mo.

AI Trained on Swedish Health Registries Flags Small Groups at High Melanoma Risk

8 ARTICLES

2mo ago

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

3 ARTICLES

2mo ago

Experimental Pill Doubles Survival in Advanced Pancreatic Cancer Trial

3 ARTICLES

2mo ago

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

7 ARTICLES

3mo ago

Androgen Signaling Drives Lethal Pediatric Ependymoma, Study Finds

4 ARTICLES

4mo ago

Study Links PSMA PET/CT to 5-Year Outcomes, Informing Salvage Treatment After Prostatectomy

7 ARTICLES

4mo ago

CNIO’s Triple-Drug Mouse Breakthrough on Pancreatic Cancer Moves Into a Cautious Preclinical Phase

3 ARTICLES

4mo ago

CRISPR Scan Maps the Strength of Cancer-Driving CTNNB1 Hotspot Mutations

16 ARTICLES

5mo ago

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

19 ARTICLES

5mo ago

Triple-Drug Strategy Wipes Out Pancreatic Tumors in Mice, Study Finds

Oncology

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

Tumor Inflammation Drives Early Resistance to KRAS Drugs, Study Shows

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

Boehringer’s Zongertinib Wins China Conditional Approval as ASCO Data Show Patient Benefit and Broader Activity

GLP-1 Drugs Linked to Lower Death and Recurrence in Breast Cancer, Large Study Finds

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

AI Blood Test Maps Tumor Neighborhoods and Predicts Immunotherapy Response

AI Pathomics Tool Beats PD-L1 at Predicting Lung Cancer Immunotherapy Benefit

Pre-Surgery Pembrolizumab Shows Zero Relapses in MSI-High Bowel Cancer Trial

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

Never miss stories about

Oncology

AI Trained on Swedish Health Registries Flags Small Groups at High Melanoma Risk

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

Experimental Pill Doubles Survival in Advanced Pancreatic Cancer Trial

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

Androgen Signaling Drives Lethal Pediatric Ependymoma, Study Finds

Study Links PSMA PET/CT to 5-Year Outcomes, Informing Salvage Treatment After Prostatectomy

CNIO’s Triple-Drug Mouse Breakthrough on Pancreatic Cancer Moves Into a Cautious Preclinical Phase

CRISPR Scan Maps the Strength of Cancer-Driving CTNNB1 Hotspot Mutations

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

Triple-Drug Strategy Wipes Out Pancreatic Tumors in Mice, Study Finds

Never miss stories about

Oncology